# ADC Therapeutics SA (ADCT)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/adc-therapeutics-sa/ JSON: https://steadybase.io/company/adc-therapeutics-sa.json Checked Nov 21, 2026. Latest filing read: Nov 10, 2026.

## Company

- Legal name: ADC Therapeutics SA
- Ticker: ADCT (NYSE)
- SEC CIK: 0001771910
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Epalinges, V8
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: adctherapeutics.com
- LinkedIn: https://www.linkedin.com/company/adc-therapeutics
- Next earnings date: Jan 4, 2027

## Key facts

- Revenue: $81.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/0001628280-26-016491-index.html
- Operating income: -$121.5M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/0001628280-26-016491-index.html
- Net income: -$142.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/0001628280-26-016491-index.html
- SG&A: $79.9M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/0001628280-26-016491-index.html
- Shares outstanding: 127,667,695 as of Aug 3, 2026 (10-Q filed Aug 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/1771910/000162828026056711/0001628280-26-056711-index.html
- Auditor: Pricewaterhousecoopers Sa, Lausanne, Switzerland, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm

## Business

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC.S. Food and Drug Administration (“FDA”) and conditional approval from the European Commission, China National Medical Products Administration (“NMPA”) and Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $81.4M | -$121.5M | -$142.6M | $79.9M |
| Dec 31, 2024 | $70.8M | -$130.7M | -$157.8M | $85.9M |
| Dec 31, 2023 | $69.6M | -$166.0M | -$240.1M | $105.9M |
| Dec 31, 2022 | $209.9M | -$123.3M | -$157.1M | $143.5M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/adc-therapeutics-sa.json

## Officers and directors

- Ameet Mallik, Chief Executive Officer of ADC Therapeutics. LinkedIn: https://linkedin.com/in/ameet-mallik-1002293. Source: 8-K filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000095010326016945/dp256258_ex9901.htm
- Jose Carmona, Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/jose-ignacio-carmona-636462. Source: Form 4 filed Jul 2, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000162828026047033/0001628280-26-047033-index.htm
- Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. LinkedIn: https://linkedin.com/in/mohamed-zaki-59aa815. Source: 8-K filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000095010326016945/dp256258_ex9901.htm
- Peter J. Graham, Chief Legal Officer. LinkedIn: https://linkedin.com/in/peter-graham-89827474. Source: Form 4 filed Jul 2, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000162828026047034/0001628280-26-047034-index.htm
- Lisa Kallebo, Corporate Controller and Chief Accounting Officer. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm
- Lisa Michelle Kallebo, Chief Accounting Officer. Source: Form 4 filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000162828026009283/0001628280-26-009283-index.htm
- Ron Squarer, Chairman of the Board of Directors. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm
- Jean-Pierre Bizzari, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm
- Peter Hug, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm
- Robert Azelby, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm
- Timothy Coughlin, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm
- Tyrell Rivers, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm
- Victor Sandor, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm
- Viviane Monges, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm
- Jean-Pierre Bizzari, M.D., Board member (per proxy). Source: DEF 14A filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm
- Jose “Pepe” Carmona, Named in proxy. LinkedIn: https://www.linkedin.com/in/jose-ignacio-carmona-636462. Source: DEF 14A filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm
- Mohamed Zaki, M.D., Ph.D., Named in proxy. Source: DEF 14A filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm
- Peter Graham, Named in proxy. Source: DEF 14A filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm
- Timothy Coughlin, CPA, Board member (per proxy). Source: DEF 14A filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm

## Recent 8-K events

- Nov 9, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1771910/000162828026071899/adc-20261109.htm
- Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1771910/000095010326016945/dp256258_8k.htm
- Oct 13, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.02, Results of operations and financial condition (earnings release); Item 3.02, Unregistered sales of equity securities; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1771910/000095010326015465/dp254756_8k.htm
- Aug 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1771910/000095010326012287/dp251718_8k.htm
- Jul 2, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1771910/000095010326010195/dp249055_8k.htm
- Jun 24, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1771910/000095010326009416/dp248849_8k.htm
- Jun 3, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1771910/000095010326008465/dp247928_8k.htm
- Jun 2, 2026: Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/dp247757_8k.htm
- May 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/adc-20260504.htm
- Mar 10, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1771910/000162828026016238/adc-20260310.htm

## What management said

- "During the third quarter, we made meaningful progress toward strengthening ADC Therapeutics' balance sheet and increasing strategic optionality while advancing clinical opportunities for ZYNLONTA®" Ameet Mallik, Chief Executive Officer of ADC Therapeutics (8-K filed Nov 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1771910/000162828026071899/adct-20260930pressrelease.htm
- "We are pleased by the breadth of the ZYNLONTA clinical program and the growing body of evidence showcased through multiple presentations at ASH" Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1771910/000095010326016945/dp256258_ex9901.htm
- "We believe the emerging data from LOTIS-7 and MZL reinforce the best-in-class potential of ZYNLONTA in these settings and support our pursuit of an expanded role in treating these B-cell malignancies through potential compendia and regulatory pathways" Ameet Mallik, Chief Executive Officer of ADC Therapeutics (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1771910/000095010326016945/dp256258_ex9901.htm

## Latest filings

- 8-K filed Oct 13, 2026: https://www.sec.gov/Archives/edgar/data/1771910/000095010326015465/dp254756_8k.htm
- 10-K filed Mar 10, 2026: https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm
- 10-Q filed Aug 13, 2026: https://www.sec.gov/Archives/edgar/data/1771910/000162828026056711/adc-20260630.htm
- 20f filed Mar 15, 2023: https://www.sec.gov/Archives/edgar/data/1771910/000162828023008056/adc-20221231.htm
- DEF 14A filed Apr 20, 2026: https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

